François Chabot
Research Subjects
François Chabot has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Emmanuel Gomez
9 shared publicationsAri Chaouat
7 shared publicationsAnne Guillaumot
5 shared publications- Ari Chaouat
Service des Maladies Respiratoires et Réanimation Respiratoire, Hôpital de Brabois d’Adultes, CHU de Nancy, Allée du Morvan, 54511 Vandœuvre-lès-Nancy cedex, France
3 shared publications - Christine Selton-Suty
Cardiology, CHRU de Nancy, Nancy, France
2 shared publications E. Gomez
Service des maladies respiratoires et réanimation respiratoire, université de Lorraine, hôpitaux de Brabois, CHU de Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France
2 shared publications
Latest Publications
- Open Access
- 16 May 2019
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 19 (1) , 1-7
Prevalence and management of chronic breathlessness in COPD in a tertiary care center
Breathlessness is the prominent symptom of chronic obstructive pulmonary disease (COPD). Despite optimal therapeutic management including pharmacological and non-pharmacological interventions, many COPD patients exhibit significant breathlessness. Chronic breathlessness is defined as breathlessness that persists despite optimal treatment of the underlying disease. Because of the major disability related to chronic breathlessness, symptomatic treatments including opioids have been recommended by several authors. The prevalence of chronic breathlessness in COPD and its management in routine clinical practice have been poorly investigated. Our aim was to examine prevalence, associated characteristics and management of chronic breathlessness in patients with COPD recruited in a real-life tertiary hospital-based cohort. A prospective study was conducted among 120 consecutive COPD patients recruited, in stable condition, at Nancy University Hospital, France. In parallel, 88 pulmonologists of the same geographical region were asked to respond to an on-line questionnaire on breathlessness management. Sixty four (53%) patients had severe breathlessness (modified Medical Research Council scale≥3), despite optimal inhaled medications for 94% of them; 40% had undergone pulmonary rehabilitation within the past 2 years. The severity of breathlessness increased with increasing airflow limitation. Breathlessness was associated with increased symptoms of anxiety, depression and with osteoporosis. No relation was found with other symptoms, exacerbation rate, or cardiovascular comorbidities. Among the patients with chronic breathlessness and Hospitalized Anxiety and/or Depression score > 10, only 25% were treated with antidepressant or anxiolytic. Among the pulmonologists 46 (52%) answered to the questionnaire and expressed a high willingness to prescribe opioids forchronic breathlessness, which contrasted with the finding that none of these patients received such treatments against breathlessness. Treatment approaches to breathlessness and associated psychological distress are insufficient in COPD. This study highlights underuse of pulmonary rehabilitation and symptomatic treatment for breathlessness.
- 16 May 2019
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 19 (1) , 1-7
Open AccessPrevalence and management of chronic breathlessness in COPD in a tertiary care center
Breathlessness is the prominent symptom of chronic obstructive pulmonary disease (COPD). Despite optimal therapeutic management including pharmacological and non-pharmacological interventions, many COPD patients exhibit significant breathlessness. Chronic breathlessness is defined as breathlessness that persists despite optimal treatment of the underlying disease. Because of the major disability related to chronic breathlessness, symptomatic treatments including opioids have been recommended by several authors. The prevalence of chronic breathlessness in COPD and its management in routine clinical practice have been poorly investigated. Our aim was to examine prevalence, associated characteristics and management of chronic breathlessness in patients with COPD recruited in a real-life tertiary hospital-based cohort. A prospective study was conducted among 120 consecutive COPD patients recruited, in stable condition, at Nancy University Hospital, France. In parallel, 88 pulmonologists of the same geographical region were asked to respond to an on-line questionnaire on breathlessness management. Sixty four (53%) patients had severe breathlessness (modified Medical Research Council scale≥3), despite optimal inhaled medications for 94% of them; 40% had undergone pulmonary rehabilitation within the past 2 years. The severity of breathlessness increased with increasing airflow limitation. Breathlessness was associated with increased symptoms of anxiety, depression and with osteoporosis. No relation was found with other symptoms, exacerbation rate, or cardiovascular comorbidities. Among the patients with chronic breathlessness and Hospitalized Anxiety and/or Depression score > 10, only 25% were treated with antidepressant or anxiolytic. Among the pulmonologists 46 (52%) answered to the questionnaire and expressed a high willingness to prescribe opioids forchronic breathlessness, which contrasted with the finding that none of these patients received such treatments against breathlessness. Treatment approaches to breathlessness and associated psychological distress are insufficient in COPD. This study highlights underuse of pulmonary rehabilitation and symptomatic treatment for breathlessness.
- 1 April 2017
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 34 (4) , 327-330
Quelles sont les définitions d’une exacerbation et d’une décompensation de BPCO ?
- 1 April 2017
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 34 (4) , 327-330
Quelles sont les définitions d’une exacerbation et d’une décompensation de BPCO ?
- 1 May 2015
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 7 (3) , 246
32 Non-invasive multi-modality imaging evaluation of pulmonary arterial elastance in patients with pulmonary hypertension
- 1 May 2015
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 7 (3) , 246
32 Non-invasive multi-modality imaging evaluation of pulmonary arterial elastance in patients with pulmonary hypertension
- 1 March 2014
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 31 (3) , 259-262
Le carcinome bronchiolo-alvéolaire, une cause exceptionnelle de pneumopathie infiltrante diffuse au cours d’une leucémie aiguë myéloïde
- 1 March 2014
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 31 (3) , 259-262
Le carcinome bronchiolo-alvéolaire, une cause exceptionnelle de pneumopathie infiltrante diffuse au cours d’une leucémie aiguë myéloïde
- 1 November 2011
- Vol. 61 (9) , 1283-90
[Chronic respiratory failure].
- 1 June 2011
- Vol. 61 (6) , 781-6
[From COPD to chronic respiratory failure].
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow obstruction, leading to an airflow limitation that is not fully reversible, with extrapulmonary effects or comorbidities that may contribute to the severity of the disease. The most important cause is tobacco smoking that is associated with an abnormal inflammatory pulmonary and systemic response. Chronic airflow obstruction is defined by postbronchodilator FEV1/FVC ratio < 0.7. A spirometric classification of the COPD severity is recommended into four stages. COPD has a variable natural history. Usually, COPD is a progressive disease with an increase in airways obstruction. Airflow limitation leads to hyperinflation, the most important cause of dyspnea in COPD patients. Assessment of the prognosis is based on the severity of the spirometric abnormality (FEV1) and includes other factors such as body mass index (BMI), dyspnea and exercise impairment. The underlying disease process in COPD leads to gas exchange abnormalities, chronic respiratory insufficiency and pulmonary hypertension. The more frequent causes of death are respiratory insufficiency, cardiovascular comorbidities and lung cancer.
- 1 June 2011
- Vol. 61 (6) , 781-6
[From COPD to chronic respiratory failure].
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow obstruction, leading to an airflow limitation that is not fully reversible, with extrapulmonary effects or comorbidities that may contribute to the severity of the disease. The most important cause is tobacco smoking that is associated with an abnormal inflammatory pulmonary and systemic response. Chronic airflow obstruction is defined by postbronchodilator FEV1/FVC ratio < 0.7. A spirometric classification of the COPD severity is recommended into four stages. COPD has a variable natural history. Usually, COPD is a progressive disease with an increase in airways obstruction. Airflow limitation leads to hyperinflation, the most important cause of dyspnea in COPD patients. Assessment of the prognosis is based on the severity of the spirometric abnormality (FEV1) and includes other factors such as body mass index (BMI), dyspnea and exercise impairment. The underlying disease process in COPD leads to gas exchange abnormalities, chronic respiratory insufficiency and pulmonary hypertension. The more frequent causes of death are respiratory insufficiency, cardiovascular comorbidities and lung cancer.
- 1 June 2011
- Vol. 61 (6) , 783
[Classification of COPD and prognostic factors].
- 1 June 2011
- Vol. 61 (6) , 784-5
[What are the mechanisms of obstruction in COPD?].
- 1 June 2011
- Vol. 61 (6) , 788
[Disproportionate pulmonary hypertension in COPD].
- 1 June 2011
- Vol. 61 (6) , 787
[What are the mechanisms of breathlessness in COPD?].